ReferenceID 1853
Evodiamine Inhibits Helicobacter pylori Growth and Helicobacter pylori-Induced Inflammation
Int J Mol Sci
Helicobacter pylori (H. pylori) classified as a class I carcinogen by the World Health Organization (WHO) plays an important role in the progression of chronic gastritis and the development of gastric cancer. A major bio
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final reference record.
- Reference Id
- 1853
- Evidence Id
- 18443
- Core Evidence Id
- 18443
- Source Reference Id
- 3699
- Herb2 Reference Id
- HBREF004496
- Subject Paper Key
- HBIN026264_33806161
- Pubmed Id
- 33806161
- Doi
- 10.3390/ijms22073385
- Paper Title
- Evodiamine Inhibits Helicobacter pylori Growth and Helicobacter pylori-Induced Inflammation
- Paper Abstract
- Helicobacter pylori (H. pylori) classified as a class I carcinogen by the World Health Organization (WHO) plays an important role in the progression of chronic gastritis and the development of gastric cancer. A major bioactive component of Evodia rutaecarpa, evodiamine, has been known for its anti-bacterial effect and anti-cancer effects. However, the inhibitory effect of evodiamine against H. pylori is not yet known and the inhibitory mechanisms of evodiamine against gastric cancer cells are yet to be elucidated concretely. In this study, therefore, anti-bacterial effect of evodiamine on H. pylori growth and its inhibitory mechanisms as well as anti-inflammatory effects and its mechanisms of evodiamine on H. pylori-induced inflammation were investigated in vitr. Results of this study showed the growth of the H. pylori reference strains and clinical isolates were inhibited by evodiamine. It was considered one of the inhibitory mechanisms that evodiamine downregulated both gene expressions of replication and transcription machineries of H. pylori. Treatment of evodiamine also induced downregulation of urease and diminished translocation of cytotoxin-associated antigen A (CagA) and vacuolating cytotoxin A (VacA) proteins into gastric adenocarcinoma (AGS) cells. This may be resulted from the reduction of CagA and VacA expressions as well as the type IV secretion system (T4SS) components and secretion system subunit protein A (SecA) protein which are involved in translocation of CagA and VacA into host cells, respectively. In particular, evodiamine inhibited the activation of signaling proteins such as the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) and the mitogen-activated protein kinase (MAPK) pathway induced by H. pylori infection. It consequently might contribute to reduction of interleukin (IL)-8 production in AGS cells. Collectively, these results suggest anti-bacterial and anti-inflammatory effects of evodiamine against H. pylori.
- Journal
- Int J Mol Sci
- Publish Year
- 2021
- Experiment Subject
- ags cells
- Experiment Type
- Cell Experiment
- Phenotype Related
- Helicobacter Pylori; Chronic Gastritis; Gastric Cancer; Gastric Adenocarcinoma
- Paper Title Cn
- Paper Title En
- Evodiamine Inhibits Helicobacter pylori Growth and Helicobacter pylori-Induced Inflammation
- Bilingual Status
- semi_complete